Pfizer Inc. / FoldRx Pharmaceuticals

Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)

$1.3B Vyndaqel/Vyndamax global revenue 2020 (Pfizer reported)

Disease Overview

Transthyretin amyloidosis is a progressive disease in which misfolded TTR protein deposits as amyloid fibrils in nerves (ATTR-PN) or heart muscle (ATTR-CM), causing neuropathy, heart failure and death. Wild-type disease primarily affects older men presenting as restrictive cardiomyopathy; variant (hereditary) disease tracks specific TTR mutations. Before tafamidis, treatment options were liver transplantation for the polyneuropathy form and supportive care for cardiomyopathy.

Competitive Landscape

In 2010 the ATTR landscape had no approved disease-modifying therapy. FoldRx's tafamidis was a first-in-class TTR tetramer stabilizer with EMA filing complete and US Fast Track/Orphan status. Competing programs were earlier-stage and used different modalities: Alnylam was advancing siRNA TTR knockdown (later patisiran/Onpattro, approved 2018), Isis/Ionis was developing inotersen (antisense, approved 2018 as Tegsedi), and BridgeBio's acoramidis (later Attruby, approved 2024) was years away. Pfizer's undisclosed-value FoldRx buy looked modest at the time — the FDA initially rejected tafamidis for ATTR-PN in 2012 — but the cardiomyopathy thesis converted to a blockbuster: Vyndaqel/Vyndamax won FDA approval in 2019 and reached $1.3B global revenue in 2020 and >$3B by 2023, against analyst peak estimates of $2B+. The deal is now widely cited as one of Pfizer's highest-ROI rare-disease acquisitions of the prior decade. Defending the franchise against Alnylam's vutrisiran (Amvuttra) and BridgeBio's acoramidis is now Pfizer's central ATTR commercial challenge.